Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: Exploring the impact of ring size on structure-activity relationships

被引:61
|
作者
Romines, KR
Morris, JK
Howe, WJ
Tomich, PK
Horng, MM
Chong, KT
Hinshaw, RR
Anderson, DJ
Strohbach, JW
Turner, SR
Mizsak, SA
机构
[1] PHARMACIA & UPJOHN INC,COMP AIDED DRUG DISCOVERY,KALAMAZOO,MI 49001
[2] PHARMACIA & UPJOHN INC,CHEM & BIOL SCREENING,KALAMAZOO,MI 49001
[3] PHARMACIA & UPJOHN INC,CANC & INFECT DIS RES,KALAMAZOO,MI 49001
[4] PHARMACIA & UPJOHN INC,MED CHEM RES,KALAMAZOO,MI 49001
关键词
D O I
10.1021/jm960296c
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Previously, 3-substituted cycloalkylpyranones, such as 2d, have proven to be effective inhibitors of HIV protease. In an initial series of 3-(1-phenylpropyl) derivatives with various cycloalkyl ring sizes, the cyclooctyl analog was the most potent. We became interested in exploring the influence of other structural changes, such as substitution on the phenyl ring and saturation of the 5,6-double bond, on the cycloalkyl ring size structure-activity relationship (SAR). Saturation of the 5,6-double bond in the pyrone ring significantly impacts the SAR, altering the optimal ring size from eight to six. Substitution of a sulfonamide at the meta position of the phenyl ring dramatically increases the potency of these inhibitors, but it does not change the optimal ring size in either the cycloalkylpyranone or the cycloalkyldihydropyrone series. This work has led to the identification of compounds with superb binding affinity for the HIV protease (K-i values in the 10-50 pM range). In addition, the cycloalkyldihydropyrones showed excellent antiviral activity in cell culture, with ED(50) values as low as 1 mu M.
引用
收藏
页码:4125 / 4130
页数:6
相关论文
共 50 条
  • [41] Exploring Structure-Activity Relationships and Modes of Action of Laterocidine
    Thombare, Varsha J.
    Swarbrick, James D.
    Azad, Mohammad A. K.
    Zhu, Yan
    Lu, Jing
    Yu, Heidi Y.
    Wickremasinghe, Hasini
    He, Xiaoji
    Bandiatmakur, Mahimna
    Li, Rong
    Bergen, Phillip J.
    Velkov, Tony
    Wang, Jiping
    Roberts, Kade D.
    Li, Jian
    Patil, Nitin A.
    ACS CENTRAL SCIENCE, 2024, 10 (09) : 1703 - 1717
  • [42] Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint
    Hudson, Sarah
    Kiankarimi, Mehrak
    Eccles, Wendy
    Mostofi, Yalda S.
    Genicot, Marc J.
    Dwight, Wesley
    Fleck, Beth A.
    Gogas, Kathleen
    Wade, Warren S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (16) : 4495 - 4498
  • [43] Structure-activity relationships for the anti-HIV activity of flavonoids
    Olivero-Verbel, JD
    Pacheco-Londoño, L
    JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2002, 42 (05): : 1241 - 1246
  • [44] Structure-activity relationships of selective GABA uptake inhibitors
    Hog, Signe
    Greenwood, Jeremy R.
    Madsen, Karsten B.
    Larsson, Orla M.
    Frolund, Bente
    Schousboe, Arne
    Krogsgaard-Larsen, Povl
    Clausen, Rasmus P.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (17) : 1861 - 1882
  • [45] Structure-activity relationships for synthetic peptide inhibitors of thrombin
    Clement, CC
    Gingold, J
    Philipp, M
    FASEB JOURNAL, 2003, 17 (05): : A1006 - A1006
  • [46] An Overview of Thrombin Inhibitors in the Perspective of Structure-activity Relationships
    Wang, Jiangming
    Sun, Xiaojing
    Li, Na
    Sheng, Ruilong
    Guo, Ruihua
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (25) : 2864 - 2930
  • [47] Inhibitors of vitamin D hydroxylases: Structure-activity relationships
    Schuster, I
    Egger, H
    Nussbaumer, P
    Kroemer, RT
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 88 (02) : 372 - 380
  • [48] Structure-activity relationships of carbocyclic influenza neuraminidase inhibitors
    Williams, MA
    Lew, W
    Mendel, DB
    Tai, CY
    Escarpe, PA
    Laver, WG
    Stevens, RC
    Kim, CU
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (14) : 1837 - 1842
  • [49] Structure-activity relationships of novel potent MurF inhibitors
    Gu, YG
    Florjancic, AS
    Clark, RF
    Zhang, TY
    Cooper, CS
    Anderson, DD
    Lerner, CG
    McCall, JO
    Cai, YN
    Black-Schaefer, CL
    Stamper, GF
    Hajduk, PJ
    Beutel, BA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (01) : 267 - 270
  • [50] The development of novel telomerase inhibitors: Structure-activity relationships
    Cheng, MK
    Modi, C
    Grindon, CR
    Stevens, MFG
    Laughton, CA
    BRITISH JOURNAL OF CANCER, 2003, 88 : S40 - S40